Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146516 · ClinicalTrials.gov registry record · NA
Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)
A NA study of Stickler Syndrome Type 1 and Stickler Syndrome Type 2, sponsored by Helen Keller Eye Research Foundation.
- Recruiting
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 2
- Study locations
NCT07146516: Recruiting NA study of Stickler Syndrome Type 1 and Stickler Syndrome Type 2, sponsored by Helen Keller Eye Research Foundation.
NCT07146516 is a NA study of Stickler Syndrome Type 1 and Stickler Syndrome Type 2 that is actively recruiting participants, run by Helen Keller Eye Research Foundation. The registered enrollment target is 500 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07146516, a NA study of Stickler Syndrome Type 1 and Stickler Syndrome Type 2, is actively recruiting participants, sponsored by Helen Keller Eye Research Foundation.
- RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to prospectively document to what extent the OSC/SS prophylactic laser retinopexy procedure works to prevent retinal detachment in SS in children and adults. Researchers will compare the OSC/SS procedure in SS to the natural progression of SS to see to what extent the OSC/SS procedure works to prevent retinal detachment. Participants will: * Have the OSC/SS procedure in one or both eyes * Have eye tests * Have genetic testing for SS as needed * Visit the study center 9 times over 5 years for checkups and tests
Primary Outcome
Efficacy of the OSC/SS procedure in preventing RD in participants with type 1 (STL1) and type 2 (STL2) SS will be assessed annually by tracking the number of participants who develop RD after undergoing the OSC/SS procedure, using data from one of the following: photographic fundus mapping and IDO examinations.
Conditions Studied
Interventions
- PROCEDURE Prophylactic (non-invasive) Laser Retinopexy
Study Locations (2)
Alabama
- Retina Specialists of Alabama - Birmingham
Minnesota
- Retina Consultants of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2035-12 |
| Phase | NA |
What NCT07146516 shows while recruiting
NCT07146516 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 2 conditions, with Stickler Syndrome Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Prophylactic (non-invasive) Laser Retinopexy is the first listed.
NCT07146516 reports a single indexed study location in Alabama, Minnesota.
Frequently Asked Questions
What is clinical trial NCT07146516 about?
NCT07146516 is a clinical study titled "Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)". The goal of this clinical trial is to prospectively document to what extent the OSC/SS prophylactic laser retinopexy procedure works to prevent retinal detachment in SS in children and adults. Researchers will compare the OSC/SS procedure in SS to the natural progression of SS to see to what extent...
What is the current status of trial NCT07146516?
This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2025-10-30. Estimated completion is 2035-12.
What conditions does trial NCT07146516 study?
This clinical trial studies the following conditions: Stickler Syndrome Type 1, Stickler Syndrome Type 2.
What interventions are being tested in trial NCT07146516?
The interventions under investigation include: Prophylactic (non-invasive) Laser Retinopexy (PROCEDURE).
Who is sponsoring clinical trial NCT07146516?
This trial is sponsored by Helen Keller Eye Research Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07146516 being conducted?
This trial has 2 study locations across Alabama, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07146516's enrollment target sits among peer trials
500 193rd of 2000 higher than 1,788 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI